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Abstract
Background: Improving healthcare providers’ communication about HPV vaccination is critical to increasing uptake.
We previously demonstrated that training providers to use presumptive announcements to introduce HPV vaccination
improved uptake, whereas training them to use participatory conversations had no effect. To understand how
communication training changed provider perceptions and communication practices, we evaluated intermediate
outcomes and process measures from our randomized clinical trial, with a particular focus on identifying mechanisms
that might explain the announcement training’s impact.
Methods: In 2015, a physician educator delivered 1-h in-clinic HPV vaccination recommendation trainings at 20
primary care clinics in North Carolina serving 11,578 patients age 11 or 12. Clinics were randomized to receive training
to use “announcements” that presume parents are ready to vaccinate or “conversations” that invite dialog about
vaccination. Training participants were 83 HPV vaccine providers. Pre- and post-training surveys assessed constructs
from the theory of planned behavior (TPB), including providers’ attitudes and subjective norms about HPV vaccination
and their perceived behavioral control to recommend HPV vaccination. Surveys also assessed providers’ perceptions of
the announcement and conversation communication strategies.
Results: Both trainings improved TPB-related constructs, including providers’ positive attitudes toward HPV vaccination,
subjective norms, and perceived behavioral control to recommend the vaccine (all p < .001, Cohen’s d = .62–.90).
Furthermore, in both trainings, the amount of time providers reported needing to discuss HPV vaccination with parents
decreased from pre-training to 1-month follow-up (mean = 3.8 vs. 3.2 min, p = .01, d = .28). However, announcement
trainings outperformed conversation trainings on other measures. For example, providers who received announcement
training more often reported that the communication strategy saved them time, was easy to use, helped them promote
HPV vaccination as routine care, and increased HPV vaccination coverage in their clinics (all p < .05; d = .44–.60).
Conclusions: Both announcement and conversation trainings improved providers’ HPV vaccine-related perceptions.
However, providers viewed announcements as easier to use and more effective, which may help to explain the success
of this training approach. Future provider communication interventions should consider implementation outcomes,
including acceptability, alongside more traditional TPB constructs.
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Process assessment
Background
Human papillomavirus (HPV) vaccination can greatly re-
duce morbidity and mortality related to genital warts and
HPV-associated cancers [1, 2]. National recommendations
call for routine vaccination for females and males age 11
or 12 [3]. The vaccine may be most effective when deliv-
ered at this age because younger adolescents have a higher
immune response [4] and a low likelihood of prior expos-
ure to HPV. Many countries, including the United States
of America (USA), have moved to a two-dose schedule for
younger adolescents [5]. However, low uptake in the USA
has undermined the vaccine’s promise. Only about half of
US adolescents have received even one dose of HPV
vaccine by age 13 [6].
Healthcare providers’ recommendations are a powerful
motivator of HPV vaccine uptake, yet recommendations
are often absent or of low quality [7]. Based on national
practice recommendations and research findings,
providers should routinely recommend same-day HPV
vaccination for adolescents of both sexes at age 11 or 12
[7, 8]. However, a national survey we conducted with
776 US pediatricians and family physicians found that
many physicians (59%) recommended HPV vaccine
using a risk-based approach (i.e., recommended HPV
vaccination preferentially for those they perceived to be
at higher risk for HPV infection), and about half (49%)
recommended something other than same-day vaccin-
ation [7]. An appreciable minority of physicians did not
strongly recommend HPV vaccine (27%), or they recom-
mended vaccination after age 12 or not at all for females
(26%) or males (39%). Efforts are needed to increase
recommendation frequency and quality. These efforts
should consider facilitators of and barriers to provider
communication, including providers’ perceptions of time
constraints during the clinical encounter [9–11].
Until recently, a key barrier to improving communica-
tion about HPV vaccination was a lack of data about
how to best introduce the topic of adolescent vaccin-
ation. In their observational research to understand how
providers communicate with vaccine-hesitant parents
about early childhood vaccines, Opel and colleagues
found that most providers used one of two approaches
to initiate their vaccine recommendations: a presumptive
approach (which we refer to as an “announcement”) or a
participatory approach (or “conversation”) [12]. In the
case of announcements, providers initiated their vaccine
recommendations using statements that presumed
parents were ready to vaccinate (e.g., “Your child is due
for three vaccines”). Providers using a participatory
approach instead engaged parents in dialogue [13] (e.g.,
“What do you want to about the vaccines today?”).
To evaluate these two communication approaches
using a more rigorous study design [12, 14, 15], we
conducted a randomized clinical trial of 30 primary care
clinics in North Carolina to assess the impact of
announcement and conversation communication train-
ing on HPV vaccination coverage. We developed the
trainings based in part on the theory of planned behavior
(TPB), a theory that has shown promise in predicting
pediatricians’ HPV vaccine recommendation behaviors
[16]. This theory posits that one’s attitude toward a be-
havior, perceptions of subjective norms about a behavior,
and beliefs about one’s capability of performing a behav-
ior and its impact (i.e., perceived behavioral control)
increase intentions to act (e.g., intentions to recommend
HPV vaccine), which, in turn, leads to the behavior (e.g.,
HPV vaccine recommendation) [17]. Thus, we opera-
tionalized these TPB constructs as providers’ positive
attitudes toward, perceived subjective norms about, and
perceived behavioral control to recommend HPV vaccin-
ation. We anticipated that changes in these constructs
would lead to changes in providers’ communication
practices for recommending HPV vaccination. Formative
research to inform the trainings included national sur-
veys of US primary care physicians [7, 9] and parents of
adolescents [18]; other published findings including
those suggesting the utility of the TPB for understanding
patient-provider communication about HPV vaccine
[16]; feedback from an expert panel of pediatricians,
family physicians, other vaccine providers, and re-
searchers; and pilot testing with two clinics in North
Carolina.
Among 11- to 12-year-old patients, we found that
training providers to make presumptive announcements
about HPV vaccine increased coverage by 5%, whereas
training providers to start participatory conversations
did not result in statistically significant improvements in
coverage [19]. An important next step is to understand
the mechanisms by which communication training
worked to improve vaccine delivery by exploring pos-
sible mechanisms for the success of the announcement
arm. Thus, the aims of the present study were to evaluate
the two trainings’ impact, both overall and by trial arm, on
(1) intermediate outcomes, including providers’ TPB-
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related perceptions and self-reported recommendation
practices and (2) process measures such as acceptability.
By identifying specific ways in which announcement train-
ing outperformed conversation training, this study seeks
to inform the national dissemination of our intervention
protocol.
Methods
We conducted a randomized clinical trial to evaluate the
impact of provider trainings on HPV vaccine communi-
cation (NCT02377843). We randomly assigned clinics to
one of two intervention arms (announcement training or
conversation training) or to a waitlist control arm, and
then we recruited the clinics to meet our quota. This
article focuses on the 20 clinics that received the com-
munication trainings; we did not provide training to
clinics in the no-intervention control arm during the
follow-up period. We described our methods previously
[19] and thus present them briefly below.
Participants and setting
Clinics were eligible to enroll in the trial if they special-
ized in pediatrics or family medicine; had 100 or more
patients age 11 or 12 attributed to the clinic in the
North Carolina Immunization Registry; were located
within a 2-h drive of Chapel Hill, North Carolina; and
had at least one pediatric or family medicine physician
who provided HPV vaccine to 11- or 12-year-olds. We
identified 150 eligible clinics that we randomized. We
recruited to meet the trial quota of 10 enrolled clinics
per arm (30 clinics total). Intervention clinics received
up to $800, and their providers received up to one
continuing medical education credit for attending the
training. Because vaccine delivery happens in the context
of a health care team, both prescribing clinicians (e.g.,
physicians, physician assistants, and nurse practitioners)
and non-prescribing clinicians (e.g., nurses) participated
in trainings and completed related surveys. Given our
study’s special focus on prescribing, vaccine-prescribing
clinicians also completed a follow-up survey for which
they received $100. Providers practicing at the clinics
consented to be in the trial before the training began.
The University of North Carolina Institutional Review
Board approved the trial protocol.
Intervention
From May to August 2015, a physician educator deliv-
ered the 1-h trainings to vaccine-prescribing clinicians
and other staff at intervention clinics. The physician
educator led the four-part training using a standardized
script and PowerPoint slide set. The first section, a
review of HPV vaccination research and the reason for
focusing on younger adolescents, was designed to affect
attitudes (e.g., that their recommendation increases HPV
vaccination) and subjective norms (e.g., that parents
think HPV vaccination is important). The second and
third sections were designed to bolster providers’
perceived behavioral control (e.g., knowing how to
recommend HPV vaccine in a way that leads to vaccin-
ation). In the second section, the physician educator
taught participants a strategy for delivering effective
HPV vaccine recommendations by starting with either
an announcement or conversation strategy and then, as
needed, addressing parent questions using the EASE
approach, and recommending the vaccine. The EASE
approach to addressing questions was to elicit the par-
ent’s main concern, acknowledge the concern without
judgment, share a commitment to vaccination and the
child’s health, and explain what the science says. Train-
ings were identical except for the recommendation strat-
egy taught during this section. In the third section,
participants developed a brief script for the first step of
the strategy and practiced it with a colleague. In the last
section, participants discussed how they would apply the
recommendation strategy to their clinical practice.
Measures
Vaccine-prescribing clinicians completed three written
surveys over the course of the study: a pre-training
survey immediately prior to the start of the training, a
post-training survey at the end of the training, and a
follow-up survey by mail or online after practicing the rec-
ommendation strategy with at least five patients. Other
providers (non-vaccine prescribing clinicians) completed
only the pre- and post-training surveys. We developed
items using validated measures [7] when possible. We cre-
ated new items using a rigorous process that included pre-
testing with four physicians to assess item comprehension.
Surveys are available at http://www.unc.edu/~ntbrewer/
hpv.htm, in Additional file 1: Table S1, and in Additional
file 2.
HPV vaccine recommendation behaviors
Pre-training and 1-month follow-up surveys assessed self-
reported recommendation behavior. One item assessed
use of the announcement approach to introducing HPV
vaccination: “Some clinicians first talk about adolescent
vaccines by announcing the child is due for meningitis,
HPV, and Tdap vaccines, and then saying, ‘We’ll give those
at the end of the visit.’ How often did you use this ap-
proach when talking about HPV vaccination in the last
two weeks?” Another item assessed use of the conversa-
tion approach to introducing HPV vaccination: “Some cli-
nicians first talk about adolescent vaccines by starting a
conversation about the health benefits of meningitis, HPV,
and Tdap vaccines, and then asking, ‘What questions do
you have?’ How often did you use this approach when
talking about HPV vaccination in the last two weeks?”
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Both items examined a concurrent recommendation
for all three vaccines in the routine adolescent
immunization schedule, an approach included in the
trainings and advocated by the Centers for Disease
Control and Prevention [20]. The 5-point response
scale ranged from never to always.
Pre-training and 1-month follow-up surveys assessed
recommendation quality. The six items included four
items from a validated index about recommendation
timeliness, urgency, consistency, and strength of en-
dorsement [7], as well as two items from a recent
systematic review about emphasizing cancer prevention
and endorsing HPV vaccination as part of routine care
[8]. The 5-point response scale ranged from strongly
disagree to strongly agree. We created a recommendation
quality index by assigning 1 point for agree or strongly
agree responses and 0 points for other responses (we re-
verse coded the consistency variable), then summing re-
sponses to create a composite score (range 0–6).
Time spent discussing HPV vaccination with patients
Pre-training and 1-month follow-up surveys assessed
providers’ perceptions of the number of minutes and
seconds it usually takes to talk about HPV, Tdap, and
meningococcal vaccines.
TPB constructs
Pre- and post-training surveys included six items that
assessed TPB-related constructs so as to understand the
impact of our training on providers’ HPV vaccine-
related perceptions; 1-month follow-up surveys also
assessed three of these items. These items assessed
providers’ HPV vaccine attitudes (two items), subjective
norms about HPV vaccination (two items), and self-
efficacy to recommend HPV vaccination (which is an
aspect of perceived behavioral control, two items). We
evaluated one additional construct, behavioral inten-
tions, at post-training and 1-month follow-up with a
single item that assessed intentions to use the recom-
mendation strategy taught in the training. For all TPB
items, the 5-point response scale ranged from strongly
disagree to strongly agree.
Perceptions of the communication strategy
To evaluate the acceptability of the communication
trainings, post-training and 1-month follow-up surveys
assessed perceptions of the recommendation strategy
taught in the training (seven items). Items assessed pro-
viders’ perceptions of the extent to which using the
communication strategy is easy to do, helps them make
HPV vaccination part of routine adolescent care, helps
them address parents’ concerns, helps them emphasize
HPV vaccination as a way to prevent cancer, saves them
time, and increases HPV vaccination in their practice.
The survey also asked providers whether they thought
that parent satisfaction with clinic visits increased or
decreased as a result of using the communication strat-
egy. The 5-point response scale ranged from strongly
disagree to strongly agree, or decreased a lot to in-
creased a lot.
Data analysis
Our analysis sought to first identify how communication
training impacted intermediate outcomes and process
measures for the two trial arms combined, and then
compared the announcement training to the conversa-
tion training. We used paired t-tests to compare survey
responses across two time points (pre- vs. post-training,
or post-training vs. 1-month follow-up) and independent
samples t-tests to compare responses by trial arm. We
also examined the interaction of trial arm and time (i.e.,
pre-training and follow-up) using 2 × 2 analysis of vari-
ance (ANOVA) for mixed designs and report these when
statistically significant. Because our trial primarily
focused on vaccine-prescribing clinicians, our analyses
also focus on these providers except where noted. We
conducted analyses in SAS v. 9.4 (Cary, NC) using two-
tailed tests and a critical alpha of .05.
Results
We trained 83 vaccine-prescribing and 59 non-vaccine
prescribing clinicians practicing at 20 clinics serving
11,578 adolescents age 11 or 12 and 24,069 adolescents
ages 13 through 17. We received pre-training, post-
training, and 1-month follow-up surveys from 100% of
vaccine-prescribing clinicians. Most vaccine prescribers
were pediatricians (65%), were female (69%), and had
been practicing for at least 10 years (66%) (Table 1). The
largest proportion of providers reported seeing 10–19
patients ages 11–17 years per week (61%). Roughly half
of providers reported that about half or most of their
patient volume is comprised of 11- or 12-year-olds
(49%). Trial arms did not differ on these sample charac-
teristics (all p > .05).
HPV vaccine recommendation behaviors
Providers shifted their communication style to match
the style in the training they attended. Before the train-
ing, providers reported using conversations more often
than announcements (mean [M] = 3.5 vs. 2.5, p < .001,
Cohen’s d = .68), a finding that did not differ by trial arm
(Fig. 1). A month later, providers who received the
announcement training reported a higher frequency of
using announcements compared to providers in the con-
versation training (M = 4.0 vs. 3.3, p = .01, d = .58). Simi-
larly, providers who received the conversation training
reported a higher frequency of using conversations at 1-
month follow-up compared to providers who received
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the announcement training (M = 3.7 vs. 3.2, p = .03, d
= .49). For use of conversations, the interaction between
time and trial arm was statistically significant (p = .03)
due to rising use of conversations in the conversation
training arm and falling use in the other arm.
Quality of recommendation practices increased as well
for both trial arms combined. The recommendation quality
index increased from an average of 4.9 (standard deviation
[SD] = 1.2, range 0–6) at pre-training to 5.3 (SD = 0.7, range
2–6) at 1-month follow-up (p = .001, d = .36). In explora-
tory analyses of individual items in the recommendation
quality index, we found increases from pre-training to 1-
month follow-up in four measures: vaccine recommenda-
tion timeliness (p < .001, d = .39), urgency (p < .001, d = .49),
and strength of endorsement (p < .001, d = .50); and
promoting HPV vaccination as part of routine care (p = .02,
d = .27) (Table 2). Emphasis on cancer prevention in discus-
sions and recommendation consistency did not change.
While trial arms did not differ on recommendation quality
measures by 1-month follow-up (all p > .05), change in
recommendation quality differed for the two trial
arms (p < .05 for interaction). For conversation training par-
ticipants, the index increased from an average of 4.7 (SD =
1.4, range 0–6) at pre-training to 5.3 (SD = 0.8, range 2–6)
at 1-month follow-up (p = .001, d = .49). For announcement
training participants, there was a not statistically significant
increase in quality of recommendation practices index,
from an average of 5.2 (SD = 0.8, range 3–6) at pre-training
to 5.3 (SD = 0.6, range 4–6) at 1-month follow-up (p = .38).
Time spent discussing HPV vaccination with patients
The amount of time providers said they spent discussing
HPV vaccine decreased from pre-training to 1-month
follow-up (M = 3.8 vs. 3.2 min, p = .01, d = .28) (Fig. 2).
Time spent discussing the other vaccines did not
Table 1 Sample characteristics of vaccine-prescribing clinicians
by trial arm (n = 83)
Announcement arm
(n = 36)
n (%)
Conversation arm
(n = 47)
n (%)
p
Specialty .08
Pediatrician 22 (61) 32 (68)
Family physician 2 (6) 3 (6)
Physician assistant 3 (8) 9 (19)
Nurse practitioner 9 (25) 3 (6)
Sex .64
Male 10 (28) 16 (34)
Female 26 (72) 31 (66)
Years in practice .21
0–4 11 (31) 5 (11)
5–9 4 (11) 8 (17)
10–14 4 (11) 10 (21)
15–19 6 (17) 9 (19)
≥20 11 (31) 15 (32)
No. of 11–17-year-old
patients/week
.38
1–9 8 (22) 5 (11)
10–19 20 (56) 31 (66)
≥ 20 8 (22) 11 (23)
Portion of patient volume
that is ages 11–12
.19
Some 19 (53) 23 (49)
About half 13 (36) 23 (49)
Most 4 (11) 1 (2)
Note. Analyses for the items in the remaining tables and figures indicated no
statistically significant difference between trial arms at baseline
Fig. 1 Frequency of using announcement and conversation recommendation strategies (n = 83)
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decrease for meningitis (M = 2.0 vs. 1.7 min, p = .07) or
for Tdap (M = 1.4 vs. 1.3 min, p = .26). Providers in the
announcement arm, compared to the conversation arm,
had higher perceptions at 1-month follow-up that using
the strategy saved them time (p = .01, d = .58) (Table 3).
TPB constructs
Providers had increases in positive attitudes toward HPV
vaccination from pre- to post-training (M = 4.4 vs. 4.7,
p < .001, d = .62) (Fig. 3). They also had increases in
subjective norms (M = 3.5 vs. 4.1, p < .001, d = .90) and
perceived behavioral control to recommend the vaccine
(M = 4.1 vs. 4.6, p < .001, d = .89). Of the measures assessed
at 1-month follow-up, all remained higher than at pre-
training (all p < .01) (Table 4). Trial arms did not differ for
individual HPV vaccine perception items at post-training
(all p > .05). By 1-month follow-up, trial arms differed for
one perceived behavioral control item. Providers who re-
ceived announcement training, compared to conversation
training, reported greater levels of agreement that they felt
confident addressing parents’ concerns when discussing
HPV vaccine (M = 4.8 vs. 4.4, p < .01, d = .73). Providers’
intentions to use the recommendation strategy taught in
the training did not change from post-training to 1-month
follow-up nor did their intentions differ by training received
(announcement vs. conversation). Among non-vaccine
prescribers, participation in the training also was generally
associated with pre- to post-training increases in attitudes,
subjective norms, and perceived behavioral control (most
p < .05) (Table 5). Among non-vaccine prescribers, percep-
tions that most parents think HPV vaccination is import-
ant for their 11- or 12-year-olds did not change (p = .17).
Perceptions of the communication strategy
Announcement training, compared to conversation train-
ing, elicited more favorable post-training perceptions that
using the strategy would be easy to do (p = .02, d = .52),
help them promote HPV vaccination as part of routine
adolescent care (p = .04, d = .44), help them address
parents’ HPV vaccine concerns (p < .01, d = .63), and help
them emphasize HPV vaccine as a way to prevent cancer
(p = .02, d = .47) (Table 3). Differences between arms were
sustained at 1-month follow-up only with regard to per-
ceptions that using the strategy helps the provider make
HPV vaccination part of routine adolescent care (p < .05,
d = .42). Providers in the announcement arm also had
more favorable perceptions at 1-month follow-up that
using the strategy increased HPV vaccination in their
clinic or practice (p = .01, d = .60).
Discussion
A strong provider recommendation can substantially in-
crease HPV vaccine acceptance, but many recommenda-
tions are of low quality or absent [18]. After a 1-h in-
Table 2 HPV vaccine recommendation quality (n = 83)
Pre-training
M (SD)
One-month follow-up
M (SD)
Recommendation quality index 4.9 (1.2) 5.3 (0.7)*
Recommendation quality items
I start routinely recommending HPV vaccine when patients
turn 11 or 12. (timeliness)
4.3 (0.8) 4.6 (0.5)*
I recommend HPV vaccine more often for adolescents at higher
risk for getting HPV. (consistency, reverse coded in quality index)
3.0 (1.3) 3.0 (1.3)
When I recommend HPV vaccine, I say it is very important.
(strength of endorsement)
4.1 (0.8) 4.4 (0.6)*
When I recommend HPV vaccine, I recommend getting it that
day. (urgency)
4.2 (0.7) 4.5 (0.6)*
I promote HPV vaccination as part of routine adolescent care.
(routine care)
4.6 (0.6) 4.7 (0.5)*
When I recommend HPV vaccine, I emphasize that it can
prevent cancer. (cancer prevention)
4.7 (0.5) 4.7 (0.5)
Note. The 5-point response scale ranged from strongly disagree (coded as 1) to strongly agree (5). Table not stratified by trial arm because they largely did not differ
*p < .05
Fig. 2 Time it takes to discuss adolescent vaccines (n = 83)
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clinic training, providers in our trial reported delivering
recommendations that were stronger, timelier, more ur-
gent, and more consistent than at pre-training. Providers
also reported spending less time discussing HPV vaccin-
ation with patients following the training, suggesting
that the communication strategy learned during the
training may have helped save them time. Notably, re-
sults suggest both communication strategies largely were
well-received by the providers, but the announcement
training was somewhat better received.
Following the trainings, providers reported that the
time it took to recommend HPV vaccination fell by
about 20%, even as it remained more time-consuming to
recommend than two other adolescent vaccines. Given
that providers have little extra time, it is encouraging
that a brief continuing medical education activity could
make them more efficient while also increasing recom-
mendation quality. These benefits may be important
points to highlight when promoting the announcement
training to providers.
To the best of our knowledge, our trial is the first to
show that training can increase providers’ HPV vaccine
recommendation quality. Providers reported making rec-
ommendations that were timelier, stronger, more urgent,
and routine after the training, but in two areas quality
did not increase. Communicating HPV vaccination as
cancer prevention did not increase, perhaps because it
was already so common. However, the lack of change in
providers’ consistency of HPV vaccine recommenda-
tion—i.e., recommending vaccine for all children regard-
less of perceived HPV risk—represents a concerning
divergence from national recommendations for routine
HPV vaccine delivery [3]. Indeed, this pitfall is common,
as only 41% of physicians in a national survey reported
they avoided using a risk-based approach to recom-
mending HPV vaccine [7]. Because adolescent sexual be-
havior is unpredictable and underestimated [21, 22],
using a risk-based recommendation approach for HPV
vaccination will leave many adolescents vulnerable to
infections that may lead to cancer. Our finding high-
lights the need for further research on ways to improve
this aspect of provider communication. Modifying the
training to include a stronger emphasis on the import-
ance of and rationale for routine HPV vaccination may
improve providers’ recommendation consistency.
Our training was based in part on the TPB, which
suggests that attitudes, subjective norms, and perceived
behavioral control will motivate behavior [17], and has
been used to study patient-provider communication
about HPV vaccine [16]. Our trial saw increases in atti-
tudes, subjective norms, and perceived behavioral
Table 3 Perceptions of the communication strategy at post-training and 1-month follow-up, by trial arm (n = 83)
Announcement Conversation
Post-training
M (SD)
One-month Follow-up
M (SD)
Post-training
M (SD)
One-month Follow-up
M (SD)
Using this communication strategy [will be/is] easy for me to do. 4.7 (0.5) 4.6 (0.5) 4.4 (0.7)* 4.4 (0.5)
Using this communication strategy [will help me to promote/
helps me make] HPV vaccination [as] part of routine adolescent care.
4.8 (0.4) 4.6 (0.5) 4.6 (0.7)* 4.3 (0.7)*
Using this communication strategy [will help/helps] me address
parents’ HPV vaccine concerns.
4.8 (0.4) 4.3 (0.8) 4.4 (0.7)* 4.4 (0.7)
Using this communication strategy will help me emphasize HPV
vaccine as a way to prevent cancer.
4.9 (0.4) – 4.6 (0.7)* –
Using this communication strategy saves me time. – 4.2 (0.8) – 3.7 (0.8)*
Using this communication strategy increases HPV vaccination in
my clinic or practice.
– 4.4 (0.7) – 3.9 (0.8)*
As a result of using this communication strategy, do you think
parent satisfaction with clinic visits…a
– 3.8 (0.6) – 3.6 (0.6)
Note. Unless indicated otherwise, the response scale had 5 points that ranged from strongly disagree (coded as 1) to strongly agree (5). We did not compare
changes from post-training to 1-month follow-up within trial arms due to differences in item wording at each time point
*p < .05 between trial arms at a given time point (between subjects)
aResponse scale is 5 points, ranging from decreased a lot (coded as 1) to increased a lot (5)
– Item not assessed at this time point
Fig. 3 Increases in HPV vaccination attitudes, subjective norms, and
perceived behavioral control (n = 83)
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control, and these increases generally were sustained for
variables measured at 1-month follow-up. Providers also
indicated that they planned to use (assessed at post-
training) and routinely used (at 1-month follow-up) the
communication strategy to recommend HPV vaccine for
their adolescent patients. Non-vaccine prescribing clini-
cians who attended our trainings also reported increases
in attitudes, subjective norms, and perceived behavioral
control. This finding is important because some research
suggests that medical assistants, nurses, or other pro-
viders make the initial HPV vaccine recommendation for
patients [23].
Comparing trial arms holds substantial interest be-
cause, as we previously reported, announcement training
increased HPV vaccine coverage among young adoles-
cents, whereas conversation training did not [19]. Trial
Table 4 Theory of planned behavior constructs among vaccine-prescribing clinicians (n = 83)
Announcement arm Conversation arm
Pre-training
M (SD)
Post-training
M (SD)
One-month
follow-up
M (SD)
Pre-training
M (SD)
Post-training
M (SD)
One-month
follow-up
M (SD)
Attitudes
HPV vaccine is effective. 4.3 (0.5) 4.8 (0.4)* – 4.6 (0.7) 4.7 (0.6) –
A clinician’s recommendation greatly increases
HPV vaccination.
4.5 (0.7) 4.7 (0.5)* – 4.3 (0.7) 4.7 (0.6)* –
Subjective norms
HPV vaccine coverage is much lower than Tdap
vaccine coverage in North Carolina.
4.3 (0.8) 4.7 (0.5)* – 4.3 (0.7) 4.5 (0.7) –
Most parents think HPV vaccination is important
for their 11- or 12-year-olds.
2.7 (0.8) 3.6 (1.0)* 3.3 (1.0)* 2.7 (0.9) 3.7 (0.9)* 3.1 (0.9)*
Perceived behavioral controla
When discussing HPV vaccine, I feel confident
addressing parents’ concerns.
4.4 (0.6) 4.7 (0.5)* 4.8 (0.4)* 4.2 (0.7) 4.6 (0.5)* 4.4 (0.5)†
I know how to recommend HPV vaccine in a
way that leads to vaccination.
3.9 (0.6) 4.6 (0.5)* 4.5 (0.6)* 3.8 (0.7) 4.6 (0.5)* 4.3 (0.5)*
Behavioral intentions
I plan to [use/routinely use] this communication
strategy to recommend HPV vaccine for my
adolescent patients.
– 4.6 (1.0) 4.6 (0.8) – 4.5 (1.0) 4.4 (0.7)
Note. The 5-point response scale ranged from strongly disagree (coded as 1) to strongly agree (5)
aThe items assessed self-efficacy, which is one component of perceived behavioral control
*p < .05 compared to pre-training, within the trial arm
†p < .01 compared to the announcement arm
– Item not assessed at this time point
Table 5 Theory of planned behavior constructs among non-vaccine prescribing clinicians (n = 59)
Pre-training
M (SD)
Post-training
M (SD)
Attitudes
HPV vaccine is effective. 3.9 (0.9) 4.5 (0.6)*
A clinician’s recommendation greatly increases HPV vaccination. 4.2 (0.7) 4.5 (0.7)*
Subjective norms
HPV vaccine coverage is much lower than Tdap vaccine coverage in North Carolina. 3.8 (1.0) 4.2 (0.8)*
Most parents think HPV vaccination is important for their 11 or 12 year olds. 3.1 (0.9) 3.3 (0.9)
Perceived behavioral controla
When discussing HPV vaccine, I feel confident addressing parents’ concerns. 3.8 (0.6) 4.3 (0.6)*
I know how to recommend HPV vaccine in a way that leads to vaccination. 3.7 (0.6)b 4.3 (0.6)*
Note. The 5-point response scale ranged from strongly disagree (coded as 1) to strongly agree (5). Table not stratified by trial arm because they did not differ
aThe items assessed self-efficacy, which is one component of perceived behavioral control
bMissing data for 21 non-vaccine prescribing clinicians at pre-training due to skip pattern
*p < .05
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arms showed few differences in TPB-related perceptions
and self-reported recommendation practices, perhaps
because the portions of trainings that were designed to
affect these perceptions and practices were designed to
be the same across arms. Instead, we observed differ-
ences by trial arm in perceptions of the communication
strategy, with a fairly consistent pattern of providers
reporting more positive perceptions of the announce-
ment training. We speculate that providers perceived
announcements as being more feasible and therefore
implemented that strategy more often. It may be that
providers’ positive perceptions of the announcement
training, along with TPB-related constructs, were needed
to drive the higher HPV vaccine coverage we observed
in announcement training clinics.
Our study contributes novel findings to the HPV vac-
cination literature by examining the effects of training
on HPV vaccine recommendation behaviors, time it
takes to make these recommendations, and TPB con-
structs in the context of HPV vaccination. Its strengths
include a 100% response rate among vaccine-prescribing
physicians who attended the trainings. Limitations of
this study of providers include the relatively short, 1-
month follow-up period for some survey responses and
immediate post-training assessment of others; it is un-
clear whether changes would sustain over the long term.
Evaluating changes in constructs after the intervention
but before providers had an opportunity to change their
behavior can disentangle the impact of the intervention
from subsequent behavior which might also cause
changes in these constructs [24]. Our surveys were brief,
assessing TPB constructs with as few as two items, in an
effort to be mindful of providers’ limited time and to in-
crease the response rate. We cognitively tested our mea-
sures with four providers, but additional validation may
be warranted in future studies. Providers’ communica-
tion behaviors were self-reported and may reflect social
desirability or other biases. Furthermore, we used
within-arm comparisons to examine changes over time
that coincided with the training. The analysis approach
yields the most easily interpreted findings when compar-
ing measures between pre- and immediate post-training,
but comparisons to 1-month follow-up did not account
for secular trends. We previously reported that interven-
tion reach and dose received were similarly high among
vaccine prescribers in both trial arms [19]; however,
implementation outcomes and contextual factors that
we did not assess may further explain our trial out-
comes. While it is encouraging that intentions to use the
training approach were high and did not drop over the
1-month follow-up period, the absence of a baseline as-
sessment meant we could not compare these measures
to before we taught the communication approach. We
also did not assess the broader construct of intentions to
recommend HPV vaccination to all eligible patients. Fu-
ture studies are needed to understand how communica-
tion training affects the experience of adolescent
patients and their parents; like providers, families may
appreciate spending less time on routine preventive ser-
vices so as to focus on more complex health issues, such
as diabetes, asthma, and depression. Finally, future
studies should consider collecting survey outcomes and
process data from providers in the control arm. These
data would offer additional insight into how the train-
ings acted on the TPB constructs.
Implications for implementation science
Similar to other studies that have used the TPB to guide
theory-based evaluations alongside trials [25–28], we
found that the TPB was a useful tool for investigating
the mechanisms for the trainings’ overall impact on pro-
viders. In our trial, we observed pre-/post-training
changes in TPB constructs, which is helpful for confirm-
ing that participating providers engaged with the train-
ing. However, improvements in TPB constructs largely
did not differ across trial arms and, therefore, do not
seem to explain why the announcement training was
effective but the conversation training was not. Instead,
providers’ favorable perceptions (or acceptability) of the
announcement training may have been an underlying
mechanism for the announcement training’s success.
The implications of our findings are that TPB constructs
may not be sufficient for understanding intervention im-
pact and likely need to be considered in the context of
implementation outcomes, such as acceptability [29].
Conclusions
Physician-led trainings increased providers’ support for
HPV vaccination and the quality of their recommenda-
tions and saved them time when recommending the
vaccine. Training providers to use announcements could
help them make effective recommendations to their
patients and, ultimately, reduce the incidence of HPV
cancers. Future provider communication interventions
should consider implementation outcomes, including ac-
ceptability, alongside more traditional TPB constructs.
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